MENUNews Archive
Date: 02/23/2016
A new study suggests that up to 60 percent of the CT scans, bone scans, and PET scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record review.
Date: 02/23/2016
A new study suggests that one approach to watching for a cancer’s return is being inappropriately used at many hospitals. And it isn’t helping patients survive longer, the research shows.
Date: 02/18/2016
Researchers at the University of Michigan Kellogg Eye Center have developed a new nanoparticle that uses a tumor cell’s protective mechanism against itself — short-circuiting tumor cell metabolism and killing tumor cells.
Date: 02/05/2016
One of the most common cancer-causing genes has continuously stymied researchers’ efforts to develop treatments against it. Now, researchers have dug deeper and exposed a key interaction that may contribute to why mutations in KRAS lead to cancer.
Date: 02/03/2016
Rogel Cancer Center researcher Max S. Wicha has received a $6.5 million Outstanding Investigator Award to study cancer stem cells, the small number of cells within a tumor that fuel its growth and spread.
Date: 01/28/2016
In response to low national vaccination rates for the human papillomavirus, the University of Michigan Rogel Cancer Center has joined 69 of the nation’s top cancer centers in issuing a statement urging for increased HPV vaccination for the prevention of cancer.
Date: 01/26/2016
Nearly 15 percent of patients diagnosed with colorectal cancer were younger than 50, the age at which screening recommendations begin.
Date: 01/21/2016
A new University of Michigan study found that feeding rats a "nisin milkshake" killed 70-80 percent of head and neck tumor cells after nine weeks and extended survival, said Dr. Yvonne Kapila, a professor at the University of Michigan School of Dentistry.
Date: 01/05/2016
Millendo Therapeutics, a University of Michigan startup company, announced today that it has entered into an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
Date: 12/23/2015
Researchers found that only 55 percent of colorectal cancer patients who were employed at the time of diagnosis retained their jobs after treatment. Patients who had paid sick leave were nearly twice as likely to retain their jobs as those without paid sick leave.